<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01450878</url>
  </required_header>
  <id_info>
    <org_study_id>I09002 FRETEP</org_study_id>
    <nct_id>NCT01450878</nct_id>
  </id_info>
  <brief_title>Renal Graft Function After Treatment With Erythropoietin (EPO)</brief_title>
  <acronym>FRETEP</acronym>
  <official_title>Interest of a High Dose of Erythropoietin Administered During Graft Processing for Early Graft Outcome in Kidney Transplant Recipients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background : Numerous studies have outlined the cellular pleiotropic effects of
      erythropoietin (EPO) and their role in the prevention of ischemic-reperfusion lesion such as
      after acute ischemic injury of the brain or the heart. However, most of these studies were
      carried out in animal models and no definitive proof exists today to demonstrate that EPO has
      similar beneficial effects in human pathology.

      Purpose : The aim of the study is to demonstrate that in humans, EPO can protect against
      ischemic-reperfusion lesions in a model of ischemia i.e. kidney transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abstract : Since the discovery that EPO and its receptor are expressed in various tissues,
      numerous studies have demonstrated that EPO is not only involved in erythropoiesis but also
      exerts pleiotropic effects on cells. Among these, one of the most exciting is its role in the
      prevention of ischemic-reperfusion lesions such as after acute ischemic injury of the brain
      or the heart. However, most of these studies were carried out in animal models and no
      definitive proof exists today to demonstrate that EPO has similar beneficial effects in human
      pathology. Kidney transplantation is one ischemic situation where EPO pleiotropic effects
      could be of great interest since ischemic-reperfusion lesions have been involved in delayed
      graft function and impaired graft outcomes.

      The aim of this prospective randomized double blind study is to assess the effect of 100 000
      UI of béta-epoiétin on kidney graft function, given to the deceased donor one hour before the
      retreaval of the organ. Recipients will be followed for three months in order to evaluate
      kidney function (glomerular filtration rate) and the number of acute rejection episodes to
      determine whether beta-epoietin could modify the immunogenicity of the graft.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of patients eligible for the study.
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>a plasma creatinin level</measure>
    <time_frame>5 days</time_frame>
    <description>To assess the effect of an injection of 100 000 UI of beta-epoitein during graft processing, on the proportion of renal recipients with a plasma creatinin level below 250 µM at day 5 after transplantation in the absence of hemodialysis, death or transplantectomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of delayed graft function defined as follows:</measure>
    <time_frame>48 hours</time_frame>
    <description>The incidence of delayed graft function defined as follows: combination of the need for dialysis (except dialysis for hyperkalemia or volume overload) or creatinine reduction ratio of less than 25% within the first 48 h post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDRD glomerular filtration rate at one and three months</measure>
    <time_frame>three months</time_frame>
    <description>MDRD glomerular filtration rate at one and three months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of acute rejection during the first three months</measure>
    <time_frame>three months</time_frame>
    <description>The incidence of acute rejection during the first three months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Ischemia</condition>
  <arm_group>
    <arm_group_label>Graft with EPO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous 1000 000UI beta-epoietin one hour before organe retrieval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>graft without EPO</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no injection befoe organ retrieval</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beta-epoietin</intervention_name>
    <description>100 000UI beta-epoietin injection one hour before organ retrieval</description>
    <arm_group_label>Graft with EPO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  donor:

               -  cadaveric organ donor,

               -  age ≥ 18 years,

               -  mono-organ (kidney) retrieval,

               -  retrieval done in the centres of Limoges, Bordeaux, Toulouse, Angers, Brest,
                  Nantes, Poitiers, Rennes, Tours,

               -  hematocrit ≤ 45%.

          -  Recipient:

               -  age ≥ 18 years,

               -  on the waiting list for a kidney graft.

        Exclusion Criteria:

          -  living donors,

          -  age under 18 years,

          -  multi-organ retrieval,

          -  donor hematocrit above 45%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie ESSIG, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU LIMOGES</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'ANGERS - CHPOT</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de BORDEAUX - CHPOT</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de BORDEAUX - Service de Néphrologie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Brest</city>
        <zip>29 609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de BREST - CHPOT</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de LIMOGES - CHPOT</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de LIMOGES - Service de Néphrologie</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de NANTES - CHPOT</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de NANTES - Service de Néphrologie</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de POITIERS - CHPOT</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de RENNES - CHPOT</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de RENNES - Service de Néphrologie</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de TOULOUSE - CHPOT</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de TOULOUSE - Service de Néphrologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Néphrologie</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de TOURS - CHPOT</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2011</study_first_posted>
  <last_update_submitted>September 2, 2016</last_update_submitted>
  <last_update_submitted_qc>September 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high dose of EPO</keyword>
  <keyword>transplant kidney</keyword>
  <keyword>cadaveric organ donor</keyword>
  <keyword>mono-organ (kidney) retrieval</keyword>
  <keyword>patient</keyword>
  <keyword>kidney graft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

